Adrian S. Ray

14.3k total citations · 4 hit papers
110 papers, 7.3k citations indexed

About

Adrian S. Ray is a scholar working on Infectious Diseases, Virology and Epidemiology. According to data from OpenAlex, Adrian S. Ray has authored 110 papers receiving a total of 7.3k indexed citations (citations by other indexed papers that have themselves been cited), including 72 papers in Infectious Diseases, 39 papers in Virology and 39 papers in Epidemiology. Recurrent topics in Adrian S. Ray's work include HIV/AIDS drug development and treatment (69 papers), HIV Research and Treatment (39 papers) and Biochemical and Molecular Research (24 papers). Adrian S. Ray is often cited by papers focused on HIV/AIDS drug development and treatment (69 papers), HIV Research and Treatment (39 papers) and Biochemical and Molecular Research (24 papers). Adrian S. Ray collaborates with scholars based in United States, United Kingdom and China. Adrian S. Ray's co-authors include Tomáš Cihlář, Joy Y. Feng, Jennifer E. Vela, Eve‐Irene Lepist, Richard L. Mackman, Marshall W. Fordyce, Michael J. M. Hitchcock, Karen S. Anderson, Darius Babusis and Dustin S. Siegel and has published in prestigious journals such as Science, Journal of Biological Chemistry and Circulation.

In The Last Decade

Adrian S. Ray

110 papers receiving 7.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Coronavirus Susceptibility to the Antiviral Remdesivir (GS-5734) Is Mediated by the Viral Polymerase and the Proofreading Exoribonuclease

2018 1.0k citations Joy Y. Feng, Adrian S. Ray et al. profile →
GS-5734 and its parent nucleoside analog inhibit Filo-, Pneumo-, and Paramyxoviruses

2017 361 citations Michel Perron, Adrian S. Ray et al. profile →
Tenofovir alafenamide: A novel prodrug of tenofovir for the treatment of Human Immunodeficiency Virus

2015 309 citations Adrian S. Ray et al. Antiviral Research profile →
GS-0976 Reduces Hepatic Steatosis and Fibrosis Markers in Patients With Nonalcoholic Fatty Liver Disease

2018 257 citations Rohit Loomba, Zeid Kayali et al. Gastroenterology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Adrian S. Ray United States	44	4.4k	2.0k	1.7k	1.6k	960	110	7.3k
Tomáš Cihlář United States	51	7.8k 1.8×	2.8k 1.4×	2.6k 1.6×	2.2k 1.4×	555 0.6×	143	11.3k
Saye Khoo United Kingdom	50	6.0k 1.3×	2.1k 1.1×	3.0k 1.8×	749 0.5×	717 0.7×	331	9.0k
Antonio D’Avolio Italy	36	2.5k 0.6×	1.2k 0.6×	857 0.5×	632 0.4×	846 0.9×	323	5.4k
Oscar L. Laskin United States	25	2.8k 0.6×	2.3k 1.2×	2.1k 1.3×	695 0.4×	267 0.3×	43	5.7k
Roy M. Gulick United States	50	8.3k 1.9×	1.9k 0.9×	6.7k 4.0×	883 0.5×	526 0.5×	168	10.6k
Alwin D. R. Huitema Netherlands	56	2.0k 0.4×	1.2k 0.6×	1.0k 0.6×	2.9k 1.8×	320 0.3×	552	12.9k
Courtney V. Fletcher United States	48	5.5k 1.2×	2.1k 1.1×	4.2k 2.5×	702 0.4×	489 0.5×	230	8.4k
David Back United Kingdom	60	8.0k 1.8×	2.1k 1.1×	4.7k 2.8×	1.3k 0.8×	1.1k 1.2×	364	13.4k
Edward P. Acosta United States	49	5.7k 1.3×	1.6k 0.8×	4.0k 2.4×	965 0.6×	272 0.3×	214	8.1k
Paul Deutsch United States	38	4.5k 1.0×	1.4k 0.7×	4.5k 2.7×	1.9k 1.2×	432 0.5×	64	8.6k

Countries citing papers authored by Adrian S. Ray

Since Specialization

Citations

This map shows the geographic impact of Adrian S. Ray's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Adrian S. Ray with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Adrian S. Ray more than expected).

Fields of papers citing papers by Adrian S. Ray

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Adrian S. Ray. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Adrian S. Ray. The network helps show where Adrian S. Ray may publish in the future.

Co-authorship network of co-authors of Adrian S. Ray

This figure shows the co-authorship network connecting the top 25 collaborators of Adrian S. Ray. A scholar is included among the top collaborators of Adrian S. Ray based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Adrian S. Ray. Adrian S. Ray is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Ray, Adrian S., et al.. (2023). P102 A small molecule selective integrin α4β7 inhibitor demonstrates efficacy in a chronic model of Inflammatory Bowel Disease. Journal of Crohn s and Colitis. 17(Supplement_1). i265–i266. 1 indexed citations

Wang, Ting, Karen Schwartz, Peidong Fan, et al.. (2020). Direct Measurement of the Intracellular Concentration of 8-Oxo-2'-Deoxyguanosine-5'-Triphosphate by LC-MS/MS. Journal of Bioanalysis & Biomedicine. 12(6). 1–8. 1 indexed citations

Liclican, Albert, Weimei Xing, Gregg Czerwieniec, et al.. (2020). Biochemical characterization of tirabrutinib and other irreversible inhibitors of Bruton's tyrosine kinase reveals differences in on - and off - target inhibition. Biochimica et Biophysica Acta (BBA) - General Subjects. 1864(4). 129531–129531. 74 indexed citations

Loomba, Rohit, Zeid Kayali, Mazen Noureddin, et al.. (2018). GS-0976 Reduces Hepatic Steatosis and Fibrosis Markers in Patients With Nonalcoholic Fatty Liver Disease. Gastroenterology. 155(5). 1463–1473.e6. 257 indexed citations breakdown →

Giacomini, Marilyn M., Hao Jia, Xiaomin Liang, et al.. (2016). Interaction of 2,4-Diaminopyrimidine–Containing Drugs Including Fedratinib and Trimethoprim with Thiamine Transporters. Drug Metabolism and Disposition. 45(1). 76–85. 29 indexed citations

Appleby, T.C., Jason K. Perry, Eisuke Murakami, et al.. (2015). Structural basis for RNA replication by the hepatitis C virus polymerase. Science. 347(6223). 771–775. 254 indexed citations

Feng, Joy Y., Yili Xu, Ona Barauskas, et al.. (2015). Role of Mitochondrial RNA Polymerase in the Toxicity of Nucleotide Inhibitors of Hepatitis C Virus. Antimicrobial Agents and Chemotherapy. 60(2). 806–817. 62 indexed citations

Lepist, Eve‐Irene & Adrian S. Ray. (2012). Renal drug–drug interactions: what we have learned and where we are going. Expert Opinion on Drug Metabolism & Toxicology. 8(4). 433–448. 50 indexed citations

Cheng, Genhong, Martijn Fenaux, Eric Mabery, et al.. (2011). 1198 NUCLEOTIDE INHIBITOR RESISTANCE SELECTIONS USING GT2A INFECTIOUS VIRUS: PSI-7851 AND GS-6620 SELECT FOR A NOVEL RESISTANCE PATHWAY INCLUDING SUBSTITUTIONS OF M289V/L FOLLOWED BY S282T. Journal of Hepatology. 54. S473–S473. 7 indexed citations

10.

Ray, Adrian S. & Karl Y. Hostetler. (2011). Application of kinase bypass strategies to nucleoside antivirals. Antiviral Research. 92(2). 277–291. 36 indexed citations

11.

Watkins, William J., Adrian S. Ray, & Lee S. Chong. (2010). HCV NS5B polymerase inhibitors.. PubMed. 13(4). 441–65. 27 indexed citations

12.

Tsai, Cheng‐Yu, Adrian S. Ray, Daniel B. Tumas, et al.. (2009). Targeting DNA Repair in Chronic Lymphocytic Leukemia Cells with a Novel Acyclic Nucleotide Analogue, GS-9219. Clinical Cancer Research. 15(11). 3760–3769. 11 indexed citations

13.

Cihlář, Tomáš, Adrian S. Ray, Geneviève Laflamme, et al.. (2007). Molecular Assessment of the Potential for Renal Drug Interactions between Tenofovir and HIV Protease Inhibitors. Antiviral Therapy. 12(2). 267–272. 83 indexed citations

14.

Ray, Adrian S., Tomáš Cihlář, L. Tong, et al.. (2006). Mechanism of Active Renal Tubular Efflux of Tenofovir. Antimicrobial Agents and Chemotherapy. 50(10). 3297–3304. 269 indexed citations

15.

Martarello, Laurent, Maaz S. Ahmed, V J Cunningham, et al.. (2005). RADIOLABELLING AND IN VIVO EVALUATION OF [C-11]GSK215083 AS A POTENTIAL 5-HT6 PET RADIOLIGAND IN THE PORCINE BRAIN. Journal of Labelled Compounds and Radiopharmaceuticals. 48. 3 indexed citations

16.

Ray, Adrian S., et al.. (2004). Effective metabolism and long intracellular half life of the anti-Hepatitis B agent adefovir in hepatic cells. Biochemical Pharmacology. 68(9). 1825–1831. 30 indexed citations

17.

Murakami, Eisuke, Adrian S. Ray, Raymond F. Schinazi, & Karen S. Anderson. (2004). Investigating the effects of stereochemistry on incorporation and removal of 5-fluorocytidine analogs by mitochondrial DNA polymerase gamma: comparison of d- and l-D4FC-TP. Antiviral Research. 62(1). 57–64. 12 indexed citations

18.

Ray, Adrian S., Aravind Basavapathruni, & Karen S. Anderson. (2002). Mechanistic Studies to Understand the Progressive Development of Resistance in Human Immunodeficiency Virus Type 1 Reverse Transcriptase to Abacavir. Journal of Biological Chemistry. 277(43). 40479–40490. 45 indexed citations

19.

Ray, Adrian S. & Karen S. Anderson. (2001). MECHANISTIC STUDIES TO UNDERSTAND THE INHIBITION OF WILD TYPE AND MUTANT HIV-1 REVERSE TRANSCRIPTASE BY CARBOVIR-TRIPHOSPHATE. Nucleosides Nucleotides & Nucleic Acids. 20(4-7). 1247–1250. 9 indexed citations

20.

Johnson, Allison A., Adrian S. Ray, Jeremiah W. Hanes, et al.. (2001). Toxicity of Antiviral Nucleoside Analogs and the Human Mitochondrial DNA Polymerase. Journal of Biological Chemistry. 276(44). 40847–40857. 323 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact